TY - JOUR
T1 - Side effects of immunotherapy
T2 - A constant challenge for oncologists
AU - Scotte, Florian
AU - Ratta, Raffaele
AU - Beuzeboc, Philippe
N1 - Publisher Copyright:
© 2019 Lippincott Williams and Wilkins. All rights reserved.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Purpose of review Immunotherapeutic strategies have become the new paradigm of cancer care, through their new targeting and safety profile approach, and, de facto, their new monitoring and safety management challenges. Recent findings Generalities and specificities of the toxicity management related to immune checkpoint inhibitors (ICIs) are highlighted. Predictive factors of safety are issue of research and the challenge of prevention as well as monitoring are huge to alleviate toxicities and enhance safety and efficacy. Particular situations like steroids association and cost-effectiveness approach are summarized. Summary Patients as well as general practitioners, including health-caregivers, should be informed before ICI initiation of the different alert symptoms which should precede immune-related adverse events.
AB - Purpose of review Immunotherapeutic strategies have become the new paradigm of cancer care, through their new targeting and safety profile approach, and, de facto, their new monitoring and safety management challenges. Recent findings Generalities and specificities of the toxicity management related to immune checkpoint inhibitors (ICIs) are highlighted. Predictive factors of safety are issue of research and the challenge of prevention as well as monitoring are huge to alleviate toxicities and enhance safety and efficacy. Particular situations like steroids association and cost-effectiveness approach are summarized. Summary Patients as well as general practitioners, including health-caregivers, should be informed before ICI initiation of the different alert symptoms which should precede immune-related adverse events.
KW - Cancer care management
KW - Immunotherapy
KW - Safety profile
KW - Side-effects
UR - http://www.scopus.com/inward/record.url?scp=85067373839&partnerID=8YFLogxK
U2 - 10.1097/CCO.0000000000000541
DO - 10.1097/CCO.0000000000000541
M3 - Review article
C2 - 30925538
AN - SCOPUS:85067373839
SN - 1040-8746
VL - 31
SP - 280
EP - 285
JO - Current Opinion in Oncology
JF - Current Opinion in Oncology
IS - 4
ER -